-
10:31:53 AM

INVA Stock News

05/23/23 6:42 PM
Nasdaq : INVA
fda approval
Innoviva Specialty Therapeutics Announces FDA Approval for XACDURO® (sulbactam for injection; durlobactam for injection), Co-packaged for Intravenous Use
Innoviva Specialty Therapeutics, a subsidiary of Innoviva, Inc., today announced that the U.S. Food and Drug Administration approved XACDURO ®, co-packaged for intravenous use in patients 18 years of age and older for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia caused by susceptible isolates...
RHEA-AI
neutral
05/11/23 6:45 PM
Nasdaq : INVA
clinical trial
Results from Pivotal Phase 3 ATTACK Trial of Investigational Sulbactam-Durlobactam for Treatment of Serious Infections Caused by Acinetobacter Published in The Lancet Infectious Diseases
Innoviva Specialty Therapeutics, a subsidiary of Innoviva, Inc. focused on delivering innovative therapies in critical care and infectious disease, today announced that The Lancet Infectious Diseases published detailed results from the pivotal Phase 3 ATTACK trial of sulbactam-durlobactam, the first pathogen-targeted therapy being studied for the...
RHEA-AI
neutral
05/09/23 4:32 PM
Nasdaq : INVA
earnings
Innoviva Reports First Quarter 2023 Financial Results and Highlights Recent Company Progress
Gross royalty revenue from Glaxo Group Limited for the first quarter 2023 was $60.3 million, which included royalties of $50.9 million from global net sales of RELVAR ®/ BREO ® ELLIPTA ® and royalties of $9.4 million from global net sales of ANORO ® ELLIPTA ®, compared to $93.5 million for the first quarter of 2022. The decrease was primarily due to the sale of...
RHEA-AI
neutral
03/13/23 6:24 PM
Nasdaq : INVA
Innoviva Announces FDA Advisory Committee Meeting to Review Sulbactam-Durlobactam (SUL-DUR), an Investigational Targeted Antibiotic
Innoviva, Inc., a diversified holding company with a portfolio of royalties and other healthcare assets, today announced that the U.S. Food and Drug Administration’ s Antimicrobial Drugs Advisory Committee will convene April 17, 2023 to review data supporting the new drug application for sulbactam-durlobactam. Carbapenem-resistant Acinetobacter is...
RHEA-AI
neutral
02/28/23 4:10 PM
Nasdaq : INVA
earnings
Innoviva Reports Fourth Quarter 2022 Financial Results and Highlights Recent Company Progress
Innoviva, Inc., a diversified holding company with a portfolio of royalties and other healthcare assets, today reported financial results for the fourth quarter ended December 31, 2022. Gross royalty revenues of $54.7 million from Glaxo Group Limited for the fourth quarter of 2022 included royalties of $44.3 million from global net sales of RELVAR ®/ BREO ®...
RHEA-AI
neutral